ErnieBilco
2月前
Meet the micro-cap biotech company reinventing regenerative medicine
May 07 2026 - 12:18PM
IH Market News
It’s a well-known and almost quaint fact that the human body is capable of regeneration. When we suffer a minor scrape or a cut, a little disinfectant, a band-aid and a few days is all it usually takes to be as good as new.
But the body’s regenerative powers are not evenly distributed. Skin, blood and certain tissues can repair themselves relatively well, while the central nervous system, including the brain, spinal cord and optic nerve, is a much more difficult frontier. Once neurons and their connections are severely damaged, the body has limited ability to rebuild them on its own, leaving patients at risk of permanent losses in movement, sensation or vision.
This is why the field of regenerative medicine is focused on ways to help the body replace or repair diseased or damaged cells through stem cells, monoclonal antibodies and even electrical stimulation. Over the past 60 years, advances such as the first bone marrow transplant in 1968 have helped catalyze this field.
That said, stem-cell-based regenerative medicine still faces major hurdles. Living-cell therapies are difficult to manufacture consistently, reproduce from batch to batch, store and scale. They may also face donor variability, immune compatibility issues, poor survival or integration after administration, and safety concerns such as unwanted differentiation or tumorigenicity in certain settings. These limitations help explain the growing interest in acellular regenerative approaches designed to capture the signaling benefits of cells without using the cells themselves.
These limitations create a significant opportunity within the US$35 billion global regenerative medicine market, which is expected to grow by more than 150 per cent to US$90 billion by 2030. There is a lucrative pathway for biotech companies to innovate and usher the field into its next era of growth.
Introducing NurExone Biologic
One company taking up this challenge head on is NurExone Biologic (TSXV:NRX) (USOTC:NRXBF), market cap C$50.63 million, with ample early-stage preclinical evidence in support of its exosome-based therapies as treatments for central nervous system injuries, including spinal cord and optic nerve injuries, with treatment associated with improvements in functional and sensory recovery after a short treatment cycle.
This article is disseminated in partnership with NurExone Biologic Inc. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Exosomes are cell-secreted nanoparticles that may naturally home to inflamed or damaged tissue and hold potential for wide-ranging applications in wound healing and nerve growth, including aesthetic use-cases spanning skin rejuvenation, hair growth and anti-aging in a market expected to 10x over the next decade. The benefits of exosomes versus stem cells include:
No living cells – Exosome-based therapies are acellular, which may reduce certain safety, immune, and compatibility concerns associated with cell-based therapies.
Scalability – Easier and larger-batch production using 2D and 3D reactors, both of which are part of NurExone’s production process.
Storage and Handling – Exosomes can potentially be frozen and thawed without losing effectiveness. This may simplify storage, handling, and supply-chain requirements compared with living stem cells.
Minimally invasive administration, given exosomes’ affinity for distressed tissue, they support less invasive treatment approaches.
NurExone is developing its proprietary ExoTherapy platform to capitalize on exosomes’ healing and regenerative properties, deploying in-house capabilities to produce the nanoparticles, synthesize therapeutic cargo, load that cargo onto the nanoparticles and develop them into nanodrugs for testing and potential commercialization. The company has a handful of strategic unmet needs in its sights, each of which is tied to a multi-billion-dollar market.
ExoPTEN for acute spinal cord injuries
NurExone’s first nanodrug, ExoPTEN, uses as its cargo a proprietary RNA sequence to inhibit the expression of the PTEN tumor-suppressor gene, commonly found in neurons and regenerating axons, with numerous studies showing that PTEN inhibition can promote wound repair and nerve growth after injury.
ExoPTEN’s first targeted use-case is the regeneration of spinal neurons, vying to improve quality of life for the more than 900,000 new traumatic spinal cord injury patients per year representing a US$7.9 billion opportunity to ease the strain on the global healthcare system.
The drug is the first known minimally invasive therapy shown to foster nerve regeneration following a full spinal cord transection in preclinical studies. About 75 per cent of animals in the study recovered motor function and results were replicated across multiple experiments in NurExone’s labs. While monoclonal antibodies and epidural electrical stimulation can be developed into non-immunogenic, off-the-shelf products, they have not demonstrated the ability to repair a full spinal cord transection making ExoPTEN a comparatively better candidate for a new standard of care in the regenerative medicine landscape.
ExoPTEN’s promising, early-stage evidence led the US Food and Drug Administration and the European Medicines Agency to award it the Orphan Drug Designation for acute spinal cord injuries, granting NurExone potential benefits including fee reduction, an expedited clinical process, as well as 7-12 years of market protection, reinforcing the company’s pathway to clinical trials in the US and Europe.
With millions of people with spinal cord injuries standing to benefit from better treatment options, NurExone is pursuing Investigational New Drug status with the US FDA, keen to kick off phase-1 human trials in 1H 2027 and further demonstrate how its stock price is a poor reflection of the ExoTherapy platform’s clinical and commercial potential.
ExoPTEN for acute glaucoma
NurExone is also studying ExoPTEN as a therapy to treat acute glaucoma, a disease that damages the optic nerve, putting vision at risk for 350,000-700,000 new people every year. With vision loss and blindness costing the US about US$26,900 per patient annually, this equates to a more than US$9 billion opportunity, robustly incentivizing innovators like NurExone to step in and solve this global health burden.
The company has also delivered successful pre-clinical results under this indication, substantiating optic nerve healing and vision restoration in 75 per cent of animals in a study.
A larger-scale pre-clinical study is currently underway at the Sheba Medical Center, ranked as the 8th best hospital in the world by Newsweek in 2025, which will support a phase-I clinical trial envisioned for the first half of 2027.
NurExone leadership has taken its future into its own hands by establishing a US subsidiary to anchor a push into the North American market.
Exo-Top
Exo-Top, NurExone’s wholly owned US subsidiary, will lead the company’s North American manufacturing, development and commercialization strategy, harnessing a Master Cell Bank of GMP-grade human bone marrow mesenchymal stem cells (MSC) – as a foundation for exosome production, ensuring consistency during the transition from the preclinical to the commercial realm.
The US subsidiary, focused on production and supply, will work in close proximity with NurExone Biologic Ltd., tasked with R&D and product development. Exo-Top is expected to leverage a sublicense agreement that gives it biomanufacturing rights to the technology underlying the ExoTherapy platform.
Stumblebum
10月前
Good news….on Etrade it shows an $1.56 ask!….now 5 minutes later there is no bid nor ask ?
TORONTO and HAIFA, Israel and INDIANAPOLIS, Sept. 16, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical innovator in exosome-based regenerative therapies, is pleased to announce that its U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), is planning to establish its first U.S. commercial exosome production facility in Indianapolis, Indiana.
The Indianapolis facility would serve as Exo-Top’s U.S. manufacturing base, transferring NurExone’s proprietary exosome production process into the American market. The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics.
“Indiana’s commitment to building its life sciences cluster, outstanding logistics and strong incentives offer make Indianapolis the ideal home for Exo-Top, and we are honored to consider expanding into Indiana with the support of the Indiana Office of Commerce,” said Jacob Licht, CEO of Exo-Top. “By joining this ecosystem, we would contribute to Indiana’s biomanufacturing growth while securing a U.S. foundation for our therapeutic and commercial programs.”
“Indiana would be a natural fit for Exo-Top’s U.S. establishment, and we look forward to the potential high-quality jobs and local economic benefits this investment would create,” said Secretary of Commerce David Adams. “The state offers the right environment for Exo-Top to scale production and strengthen NurExone’s U.S. supply chain.”
Indiana is home to one of the largest life sciences sectors in the U.S., generating more than $99 billion in annual economic outputi and attracting over $1.5 billion in venture investments since 2019ii. Industry employment has grown nearly seven times faster than the broader private sector, supported by global anchors such as Eli Lilly and advanced logistics infrastructureiii. These strengths make Indiana a strategic and attractive location for companies like Exo-Top preparing to scale.
Exo-Top’s potential new Indianapolis operations would anchor NurExone’s North American presence, complementing the Company’s progress toward first-in-human clinical trials of ExoPTEN and its plans to uplist to a major U.S. stock exchange.
kaivamei
10月前
After learning about NRXBF from you, I looked up their presentations. There's not so much yet in peer-reviewed journals, so we are still asking ourselves, is this therapy real.
If it is, though, it is amazing, and big things will come of it.
The following is an article I found from last year, in an Israeli newspaper, Haaretz. It's basically an extended NR, written "in collaboration with" the company. Still, it gives helpful color and it reassures us that they are focusing early on protecting the IP.
Here's most of it:
Scientists Giving New Hope to People With Spinal Cord Injuries
by Galya Hipsch, with Nurexone, June 25, 2024
Prof. Shulamit Levenberg is an award-winning scientist from the Technion, renowned worldwide for her expertise in biomedical and tissue engineering. She completed her postdoctoral research at MIT in 2006 and was named one of Scientific American's Top 50 Scientists list as a "science leader" in tissue engineering. During a sabbatical, she served as a visiting professor at Harvard University. Prof. Levenberg is perhaps best known as the co-founder and chief scientific advisor of Aleph Farms, a company pioneering the new and intriguing field of cultured meat production, but her achievements extend well beyond this.
She is currently the head of the Tissue and Stem Cell Engineering Laboratory at the Faculty of Biomedical Engineering, and the head of the Center for Bioprinting at the Technion (which focuses on 3D printing of tissues) at the Technion. In addition to her activities at NurExone and Aleph Farms, she is a co-founder and scientific advisor at NanoSynex.
The fascinating story of NurExone began when the CEO of the Israel Foundation for Spinal Cord Injuries, Israel Goldberg, approached Prof. Levenberg and asked her to apply her knowledge of tissue engineering to heal paralyzed individuals. Professor Levenberg decided to take on the challenge and to explore ways to rehabilitate patients after spinal cord injury.
"Together with my doctoral students and Prof. Offen, we searched for a treatment that is minimally invasive, and we came up with exosomes (extracellular vesicles). They have unique properties that enable localized treatment, nasal administration, penetration of the blood-brain barrier (BBB) and impressive therapeutic efficacy in the spinal cord."
Growth and regeneration of nerve cells of the central nervous system
Exosomes are nanoparticles secreted by various cells, including stem cells. They have therapeutic ability and can migrate to damaged tissues in the body. Additionally, exosomes can be "loaded" with various molecules allowing them to serve as a drug delivery system for targeted medications. To address damage to the spinal cord in preclinical studies, the scientists loaded exosomes with a unique siRNA sequence to inhibit PTEN protein production in affected cells in an injured area. Upon reaching the affected area, the loaded exosomes stimulate nerve cell regeneration and rewiring in the spinal cord.
"We took exosomes and enhanced them in several ways to encourage nerve cell growth and repair. Via nasal administration, they reached the spinal cord. We saw that it worked, and it was very exciting," explained Prof. Levenberg. "We were able to take rats, whose spinal cord was completely severed, and get them back on their feet. Nasal administration of the loaded-exosome drug led to regrowth of the nerves in the spinal cord, without surgery or transplants. Based on these results, we decided to move forward with clinical research and to try to develop a product for people. ExoPTEN is being developed as a drug that can be given soon after a spinal cord injury. Any motor and sensory rehabilitation after this type of injury will be a real achievement. That's why we decided to establish NurExone Biologic together with serial biotech entrepreneur, Yoram Drucker."
Dr. Noa Avni, Director of R&D at NurExone, adds: "Exosomes can both increase regenerative capacity and reduce inflammation, creating an environment that is highly beneficial for healing. It is truly a privilege to work with Prof. Levenberg, the originator of this project, who has a deep understanding of the research and academic discovery phases. She is a great inspiration, and we meet every week to ensure we are in sync. We have a highly dedicated team of knowledgeable people who often lock our lab doors late at night. This is an area with a lot of uncertainty that demands a great deal of hard work and perseverance, and the amazing commitment of the team is a critical element."
Thinking outside the box
NurExone was registered as a company in 2020. "This is actually a tech-transfer process, a transition from science to industry, in an agreement between the commercialization companies of the Technion and Tel Aviv University," explains the CEO, Dr. Lior Shaltiel. "It is important to remember that the discovery that exosomes are therapeutic is new. The world is only now discovering this, and the number of patents being registered in the field is soaring. NurExone is among the pioneers worldwide in the area of exosomes as a platform for drug delivery, and for a young company, this is a highly significant achievement."
Lior Shaltiel is a chemical engineer with a specialization in biotechnology. He holds a master's degree in physiology and a doctorate in pharmacology from LMU University in Munich. He studied and conducted research for eight years in Germany, returning to Israel during Operation Protective Edge. Following his return, he worked at LipoCure as a returning scientist, eventually serving as R&D manager. He joined NurExone Biologic as CEO in April 2021.
In June 2022, the company chose to make a unique and bold move for a startup that is still in the preclinical trial stage: it went public on the Canadian stock exchange in Toronto and has been traded there as a public company ever since. Why would a startup that doesn't yet have a product to sell go public on the stock exchange, as opposed to following the classic process of raising money from venture capital funds?
Dr. Shaltiel: "It was definitely thinking outside the box. When an entrepreneur approaches an initial fundraiser for classic venture capital funds, they often lose some motivation because the ownership of the technology is no longer entirely theirs. With this IPO, I want to prove that there is an alternative to the standard fundraising approach for biotech companies, even in the early stages. It fit me, as CEO, like a glove. After we published our technology platform last January, the stock doubled. Since its founding, the company has already raised $15 million, with the vast majority of the money invested in research and development."
"The IPO on the Toronto Stock Exchange was also a springboard on our way to larger markets, which is part of the company's growth process," he adds. "After we registered there, we were automatically listed on seven different stock exchanges in Germany, which gives us exposure to various technology investors in the biomed field throughout Europe. We have expanded to the OTCQB in the United States."
A company with more than one product
The company currently employs 16 people in Haifa, and next month it will open a new laboratory and facility on the Technion campus.
What is the status of the company regarding regulatory approvals and proceeding to human trials?
Dr. Shaltiel: "At first, my task was to prove feasibility, to show that the results obtained in academia are indeed correct. We repeated the experiments several times, changed dosages, and proved that ExoPTEN, the initial, leading product of the company, works."
"We have already gone through the regulatory stages of several meetings with the FDA. In October 2023, the drug received FDA Orphan Drug Designation, which means that the company will be eligible for significant accommodations in the next stages, market protection of the product for up to 12 years from receiving approval, and support for the product during the clinical trials process."
"I believe that the regulatory process will go smoothly and efficiently thanks both to the excellent communication between R&D and CMC (Chemistry, Manufacturing, and Control) as well as the results of the process so far," says Dr. Ina Sarel, Head of the Regulatory and Clinical Affairs Department, who led the activities that resulted in the granting of orphan drug status to ExoPTEN. Dr. Sarel recently led a workshop at a professional conference on addressing regulatory challenges when developing clinical products based on exosomes in Boston, MA.
Intellectual property
According to Dr. Shaltiel, in addition to ExoPTEN, the company is developing two other products as part of its portfolio. "The other two products focus on the regeneration and growth of neurons through different mechanisms, targeting various proteins. We have a portfolio of products based on six families of patents. The patents cover three significant aspects of the world of exosomes: the first involves the production of exosomes in large quantities, increasing their utilization, potency and healing potential. The second aspect is how medical molecules (like siRNA) are loaded into the exosomes; this enables us to insert a wide range of molecules with specific active pharmaceutical ingredients as a foundation for other products. The third aspect covers the specific siRNA sequences that are loaded into the exosomes."
"Ultimately, our goal is to be a clinical company that brings exosome-based drugs and therapies to market, realizing the commercial potential of our technology platform. The aspiration is to reach collaborations with both large and small pharma companies," concludes Dr. Shaltiel.
Prof. Levenberg adds: "At the moment, the preclinical trials that the company is about to conduct are in animals that are more similar to the clinical situation of humans. We need to implement and test additional clinical models, at different times, at different doses, to better focus the product. Based on the results, we can move on to human clinical trials. I'm waiting for that moment. I would love to see how it works in humans, to see that it can indeed make a difference and help. We don't know how long it will take because it depends on the regulatory process and approvals, but the company is progressing very nicely and the staff is excellent. This development is good news for people with spinal cord injuries."
ErnieBilco
10月前
NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce that its preclinical data on optic nerve regeneration study was presented today at the Annual Meeting of the Association for Research in Vision and Ophthalmology (“ARVO) in Salt Lake City Utah, the world's largest and most respected vision science conference.
The data, presented by Prof. Ygal Rotenstreich, lead investigator and Director of the Retinal Research Lab at Sheba Medical Center, showed that ExoPTEN restored retinal activity and improved optic nerve structure in a controlled rat model of optic nerve compression. The study, initially announced in July and December 2024, has since been expanded to include a larger group of animals.
Prof. Ygal Rotenstreich commented “We’re proud to present this progress in optic nerve regeneration at ARVO, where the future of vision science is shaped”. He further noted “Our presentation generated a lot of interest from our peers and the scientific community who are anxiously awaiting real breakthroughs in this field.
Prof. Michael Belkin, founder of Tel Aviv University's Goldschleger Eye Research Institute where the study took place and a member of NurExone’s Scientific Advisory Board, noted “The results presented at ARVO show a distinct possibility that ExoPTEN can be used in treating optic nerve pathologies. We are proceeding to study an actual glaucoma model to examine the possibility of treating optic nerves which cause vision incapacitation from this common disease.”
Dr. Lior Shaltiel, CEO of NurExone also added “We’re seeing damaged neurons survive and regain function in models that were previously considered irreversible, challenging long-standing assumptions in neurodegeneration. Acute glaucoma carries a high risk of irreversible blindness and an associated economic burden that costs the healthcare system billions per year1. By preserving vision in even a fraction of these cases, a therapy, like ExoPTEN, could deliver clinical and economic value.”
The therapy for acute glaucoma is being developed as part of NurExone’s broader ExoTherapy™ platform, which also includes programs for spinal cord and facial nerve regeneration. In preclinical spinal cord studies, ExoPTEN restored motor function in 75% of animals following complete transection. Like its ophthalmic applications, the spinal and facial nerve programs use the same exosome-based product, supporting a modular and scalable approach to nervous system repair.
The ARVO Annual Meeting is the largest and most respected gathering in vision research, bringing together over 10,000 experts from academia, industry, and clinical practice. NurExone’s inclusion in the ARVO scientific program reflects growing recognition of exosome-based strategies as a potential new frontier in regenerative medicine.
ErnieBilco
10月前
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
C$0.78 Million Private Placement Successfully Closed
TORONTO and HAIFA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce new preclinical imaging results providing anatomical evidence consistent with structural repair of spinal cord following treatment with ExoPTEN.
An imaging-based analysis of animals treated with ExoPTEN after a spinal cord injury showed more organized spinal cord tissue compared to untreated controls. A functional assessment of this same cohort showing that 100% of animals in a higher-dose group regained motor function was published in July 2025.
“The data from the MRI with Diffusion Tensor Imaging (“MRI-DTI”) indicates that the injured spinal cords showed greater structural integrity and tissue organization when treated with ExoPTEN in the animal model. Importantly, those structurally preserved spinal cords strengthen the accumulating evidence of ExoPTEN neuroprotective and regeneration-promoting activity following spinal cord injury,” said Dr. Kineret Taler, Head of Preclinical Studies.
Unmet Need in Spinal Cord Injury and Evidence of Spinal Cord Repair
Spinal cord injury is life-altering and imposes a substantial healthcare and economic burden. Current treatments focus on stabilizing patients but do not repair damaged tissue. ExoPTEN is designed to support nerve repair and restore function. NurExone continues preparations for its first-in-human clinical trial of ExoPTEN, subject to regulatory approval.
MRI-DTI is an advanced imaging technique that maps the movement of water molecules in tissue, providing a detailed view of microstructural integrity beyond conventional MRI and effectively shows a spinal cord’s wiring.
Two key parameters are used:
Fractional Anisotropy (“FA”): Indicates alignment and preservation of nerve fibers. Higher FA values indicate stronger structural integrity.
Mean Diffusivity (“MD”): Reflects microscopic tissue architecture. Lower MD values indicate healthier cellular structure and less disruption from injury.
In ExoPTEN-treated animals, FA values were higher and MD values were lower near the injury site, suggesting more organized, structurally intact tissue.
In Figure 1A, computer-generated MRI-DTI 3D images trace the “threads” of the spinal cord. The green lines represent the direction of nerve fibers and the red arrows mark the injury site. The top row (Control) shows the injury area as frayed and disrupted in both top and side views. The bottom row (ExoPTEN-treated) shows more tracts running through the injured area.
Figures 1B and 1C show normalized FA values (Figure 1B) and MD values (Figure 1C) showing significant differences between ExoPTEN-treated and control spinal cords, indicating better structural integrity and the tissue’s microscopic architecture in the ExoPTEN-treated spinal cords.
https://ml.globenewswire.com/Resource/Download/faccedd3-99ca-41b2-b072-b8a2fb0e66f5/nrx-1308-mri.jpg
CEO Dr. Lior Shaltiel commented, “This new analytic evidence, together with previously reported functional studies demonstrating recovered walking function in small animals, creates robust, support of the strong preclinical profile of ExoPTEN in spinal cord injury.”
Private Placement
The Company is also pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 1,258,072 units (“Units”) at a price of C$0.62 per Unit for aggregate gross proceeds of C$780,004.64 (the “Offering”). The Company intends to use the proceeds of the Offering for working capital purposes.
CFO Eran Ovadya added: “This limited financing round provides us with additional resources to support our ongoing operations and drive the continued development of ExoPTEN. Notably, the round included participation from existing investors who expressed their confidence in NurExone by increasing their holdings. As we advance toward our first-in-human studies, we remain committed to prudent financial management and to creating long-term value for our stakeholders.”
Terms of the Offering
Each Unit consisted of (i) one common share in the capital of the Company (each, a “Common Share”), and (ii) one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at a price of C$0.80 per Common Share for a period of 36 months, subject to acceleration. If the daily volume weighted average trading price of the Common Shares on the TSXV for any period of 20 consecutive trading days equals or exceeds C$1.70, the Company may, upon providing written notice to the holders of the Warrants (the “Acceleration Notice”), accelerate the expiry date of the Warrants to the date that is 45 days following the date of the Acceleration Notice. If the Warrants are not exercised by the accelerated expiry date, the Warrants will expire and be of no further force or effect.
Closing of the Offering is subject to receipt of all necessary regulatory approvals, including the TSXV, and all securities issued under the Offering are subject to a statutory hold period of four months and one day from the closing of the Offering and applicable U.S. legends.
About NurExone
NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
ErnieBilco
10月前
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
Independent Study and Bioanalysis Suggests More Effective Nerve Repair and Faster Wound Healing
TORONTO and HAIFA, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced that an independent study showed that exosomes produced by NurExone outperformed a recognized commercial industry standard in areas that strongly support key healing tasks including nerve repair, wound repair, calming the immune system and rebuilding tissue. This first independent analysis highlighted the broad potential of NurExone’s exosomes for both therapeutic and aesthetics markets.
“This data confirms that the naïve exosomes that will be manufactured by our U.S. subsidiary, ExoTOP Inc. (“ExoTOP”), will carry a strong regenerative and therapeutic punch. Delivering more than twice the wound-healing signals than the industry benchmark suggests applications in aesthetic skin rejuvenation, wound care and orthopedic tissue repair”, said Jacob Licht, Chief Executive Officer of ExoTOP. “As we scale production in the United States with our patent-pending 3D production process, ExoTOP is expected to generate multiple revenue streams and provide high-performance exosomes to partners across regenerative medicine.”
“Our exosomes carry complex cargo with diverse therapeutic potential, simultaneously being effective in neuroprotection and reduction in inflammation,” said Dr. Tali Kizhner, Director of R&D of NurExone Biologic. “This combination is especially powerful in the nervous system, where inflammation usually prevents healing. The benchmarking analysis confirms that our exosomes naturally carry a significant amount of the molecular signals needed to create the conditions required for meaningful nerve regeneration.”
TAmiRNA, an ISO?13485-certified molecular-diagnostics laboratory, performed a comprehensive analysis of the EV microRNA cargo of NurExone’s exosomes and compared the results with benchmark exosomes from a commercial reference source. Based on TAmiRNA’s data, bioinformatic analyses showed that NurExone’s exosomes are enriched with microRNAs that support key healing tasks.
Importantly, these exosomes were produced from NurExone’s proprietary master cell bank, whose cells are maintained under rigorously controlled environment ensuring that every production batch delivers high-performance exosomes. This reproducibility is essential for clinical translation and future patient use.
Figure 1 suggests that NurExone’s naïve exosomes outperform the commercial reference across every pathway assessed: they exhibit ˜1.8-fold higher neurological potential, nearly double the anti-inflammatory activity, and a full two-fold increase in both tissue-regeneration and wound-healing signals. This multi-modal, high-potency profile positions the exosomes as a versatile platform for therapeutic nerve repair as well as for aesthetic regenerative and longevity applications.
https://ml.globenewswire.com/Resource/Download/adb4c1ac-d77e-4955-9ddf-39f41f799d4b/3007-julius-for-release-figure-1.jpg
The results provide strong, third-party validation of NurExone’s core technology and highlight its potential across a broad range of regenerative-medicine applications.
About TAmiRNA GmbH
Vienna-based TAmiRNA is an ISO?13485-certified molecular-diagnostics laboratory whose CE-marked biomarker kits and miND® small-RNA sequencing platform provide industry-leading, ISEV-compliant exosome analytics. Its extensive extracellular-vesicle reference database and bench-to-algorithm workflow deliver regulatory-grade, reproducible insights for precision-medicine programs.
About NurExone
NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi . Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
メールアドレスで登録
